A number of trials examined the anticancer effects of combining PARP inhibitors with other anticancer agents.146,147 The addition of VEGFI to PARP inhibition in patients with ovarian cancer has shown promising oncological effects, including longer progression-free survival when compared with PARP inhibition alone.148,149 This may, however, also increase the risk of hypertension, particularly in the case of niraparib. The gene discussed is PARP1; the disease is hypertensive disorder.